Headquartered in Wilmington, MA, Charles River Laboratories International, Inc. (CRL) is a full service, early-stage contract research organization (CRO). The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts.

The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients’ manufacturing activities. Utilizing the company’s broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market.

Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.

Through the RMS segment (18.5% of total revenue in 2022; up 7.1% from 2021), the company supplies research models to the drug development industry. It also provides a variety of related services that are designed to support clients in the use of research models in drug discovery and development.

The DSA segment (61.5%; up 16.1%) provides services that enable clients to outsource their advanced drug discovery research, related drug development activities and their regulatory-required safety testing of potential new drugs, industrial and agricultural chemicals, consumer products, veterinary medicines and medical devices.

Through the Manufacturing segment (20%, up 6.3%) the company helps ensure the safe production and release of products manufactured by its clients. The Manufacturing segment comprises three businesses: Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.